Brand Name | Status | Last Update |
---|---|---|
benefix | Biologic Licensing Application | 2010-12-16 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemophilia b | D002836 | — | D67 | 1 | 2 | 8 | 2 | 7 | 20 |
Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | 2 | 8 | 2 | 5 | 18 |
Drug common name | Nonacog alfa |
INN | nonacog alfa |
Description | BeneFIX (nonacog alfa) is a protein pharmaceutical. Nonacog alfa was first approved as Benefix on 1997-08-27. It is used to treat factor vii deficiency, hemophilia a, hemophilia b, and hypoprothrombinemias in the USA. It has been approved in Europe to treat hemophilia b. ... More |
Classification | Protein |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2109205 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 382L14738L (ChemIDplus, GSRS) |